【高盛:上调基石药业-B(02616.HK)评级至“买入” 目标价6.25港元】智通财经APP获悉,高盛发布研报称,将基石药业-B(02616.HK)评级从“中性”上调至“买入”,基于风险调整后的现金流折现法给出12个月目标价6.25港元,隐含20%上行空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.